J&J's Kenvue consumer health business prepares for stock IPO

By AP News

Share:

In this article

  • Loading...
  • Want to see what you should be buying? Check out our top picks.

Johnson & Johnson’s Kenvue consumer health business is preparing for an initial public offering of more than 151 million shares of its stock

Johnson & Johnson Talcum Powder Claim

Johnson & Johnson’s Kenvue consumer health business is preparing for an initial public offering of more than 151 million shares.

The health care giant said late Monday that the per-share IPO price for Kenvue Inc. should range between $20 and $23. J&J said Kenvue has launched a road show for its IPO. That involves the company talking to potential investors ahead of the offering.

The consumer health business sells well-known products like Band-Aids, Listerine and over-the-counter medicines such as Tylenol. J&J has said it expects an IPO by the end of the year.

J&J announced in late 2021 that it was splitting its consumer health division from the pharmaceutical and medical device divisions in a bid to make each more nimble.

-based J&J’s remaining businesses focus on pharmaceuticals and medical devices.

Kenvue has applied to list its stock under the ticker symbol “KVUE” on the New York Stock Exchange.

J&J, New Brunswick, New Jersey, will still own more than 90% of Kenvue’s shares after the IPO.

Share:

In this article:

Companies:
Johnson & Johnson

Author: AP News

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Originally published by Associated Press Valuethemarkets.com, Digitonic Ltd (and our owners, directors, officers, managers, employees, affiliates, agents and assigns) are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above.

Sign up for Investing Intel Newsletter